Evaxion Biotech (EVAX) has released an update.
Evaxion Biotech has reported promising results from its Phase 2 study of EVX-01, a personalized cancer vaccine, at the ASCO Annual Meeting 2024. The vaccine, designed using the company’s AI-Immunology platform, has shown positive immune responses in patients with advanced melanoma, with booster immunizations enhancing these effects. These developments mark significant progress in Evaxion’s commitment to advancing personalized immunotherapies for cancer treatment.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.
